| scholarly article | Q13442814 |
| P50 | author | Tara L Roberts | Q57340430 |
| P2093 | author name string | James M Lee | |
| Silvia Ling | |||
| Nicholas Nikesitch | |||
| P2860 | cites work | Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha | Q24320638 |
| Proapoptotic BAX and BAK modulate the unfolded protein response by a direct interaction with IRE1alpha | Q24322072 | ||
| Endoplasmic reticulum stress: cell life and death decisions. | Q24536108 | ||
| Initial genome sequencing and analysis of multiple myeloma | Q24629117 | ||
| Molecular mechanisms in multiple myeloma drug resistance | Q26776386 | ||
| Autophagy in plasma cell pathophysiology | Q27015920 | ||
| Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics | Q27851412 | ||
| The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress | Q28068986 | ||
| Transcriptional and epigenetic regulation of autophagy in aging | Q28083637 | ||
| Chromosome translocations in multiple myeloma | Q28199347 | ||
| Stress granules: sites of mRNA triage that regulate mRNA stability and translatability | Q28215404 | ||
| Protein degradation by the ubiquitin-proteasome pathway in normal and disease states | Q28243121 | ||
| A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance | Q28395203 | ||
| Regulated translation initiation controls stress-induced gene expression in mammalian cells | Q28506388 | ||
| CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum | Q28512249 | ||
| Autophagy: process and function | Q29547296 | ||
| Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response | Q29547299 | ||
| The mammalian unfolded protein response | Q29547400 | ||
| The unfolded protein response: controlling cell fate decisions under ER stress and beyond | Q29615499 | ||
| Autophagy counterbalances endoplasmic reticulum expansion during the unfolded protein response | Q33264844 | ||
| Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial | Q33417762 | ||
| Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology | Q33547229 | ||
| Linking ER Stress to Autophagy: Potential Implications for Cancer Therapy. | Q33633401 | ||
| MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells | Q33714747 | ||
| A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases | Q33729793 | ||
| Proteasome inhibitors: a novel class of potent and effective antitumor agents. | Q33864458 | ||
| Autophagosome formation in mammalian cells | Q33964242 | ||
| Review of 1027 patients with newly diagnosed multiple myeloma | Q35045634 | ||
| New insights into the pathophysiology of multiple myeloma | Q35215808 | ||
| A novel role for hSMG-1 in stress granule formation | Q35531069 | ||
| The unfolded protein response is shaped by the NMD pathway | Q35595494 | ||
| Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1. | Q35643032 | ||
| High expression of endoplasmic reticulum chaperone grp94 is a novel molecular hallmark of malignant plasma cells in multiple myeloma | Q35789280 | ||
| The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis | Q35830099 | ||
| Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives | Q35836881 | ||
| The specialized unfolded protein response of B lymphocytes: ATF6α-independent development of antibody-secreting B cells. | Q35981133 | ||
| A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells | Q36111590 | ||
| Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. | Q36204839 | ||
| A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance | Q36338365 | ||
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Q36384889 | ||
| Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies. | Q36472987 | ||
| Smg1 haploinsufficiency predisposes to tumor formation and inflammation | Q36568009 | ||
| Endoplasmic reticulum stress sensing in the unfolded protein response | Q36626672 | ||
| Cyclins and cell cycle control in cancer and disease | Q36796438 | ||
| Preventing the autophagic survival response by inhibition of calpain enhances the cytotoxic activity of bortezomib in vitro and in vivo | Q36893251 | ||
| Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments | Q37124391 | ||
| Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma. | Q37469859 | ||
| NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers | Q37638021 | ||
| GRP94 in ER quality control and stress responses | Q37707530 | ||
| Advances in imaging and the management of myeloma bone disease | Q37864002 | ||
| Novel proteasome inhibitors to overcome bortezomib resistance | Q37878771 | ||
| The role of autophagy in cancer: therapeutic implications | Q37924056 | ||
| Protein quality control and elimination of protein waste: the role of the ubiquitin-proteasome system | Q38121352 | ||
| Recent advances and future directions in targeting the secretory apparatus in multiple myeloma | Q38258197 | ||
| Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress | Q38343228 | ||
| Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. | Q38436359 | ||
| Immunologic approaches for the treatment of multiple myeloma | Q38692244 | ||
| Cyclin D1 unbalances the redox status controlling cell adhesion, migration, and drug resistance in myeloma cells. | Q38765278 | ||
| Review and Literature Mining on Proteostasis Factors and Cancer. | Q38950514 | ||
| Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells | Q39051768 | ||
| The remarkable multivalency of the Hsp70 chaperones | Q39144895 | ||
| Hsp70 - a master regulator in protein degradation | Q39428376 | ||
| Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells. | Q39469395 | ||
| Combined treatment with bortezomib plus bafilomycin A1 enhances the cytocidal effect and induces endoplasmic reticulum stress in U266 myeloma cells: crosstalk among proteasome, autophagy-lysosome and ER stress | Q39617626 | ||
| Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells | Q39780649 | ||
| The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib | Q39856430 | ||
| IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells | Q40108449 | ||
| Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells | Q40128062 | ||
| Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells | Q40333400 | ||
| The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma | Q41470772 | ||
| Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells | Q41907181 | ||
| Effect of autophagy on multiple myeloma cell viability | Q41938175 | ||
| Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib | Q42138375 | ||
| Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response | Q42357207 | ||
| Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma | Q42762683 | ||
| Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma. | Q42940075 | ||
| Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. | Q46266877 | ||
| No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib | Q46635296 | ||
| Blocking protein quality control to counter hereditary cancers | Q47988257 | ||
| Blimp-1 Is Required for the Formation of Immunoglobulin Secreting Plasma Cells and Pre-Plasma Memory B Cells | Q52005022 | ||
| Pathogenesis of myeloma bone disease. | Q55052458 | ||
| Transcriptional features of multiple myeloma patients with chromosome 1q gain | Q60197205 | ||
| Case report. Non-secretory multiple myeloma presenting with diffuse sclerosis of affected bones interspersed with osteolytic lesions | Q83236653 | ||
| Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen | Q84948335 | ||
| Multiple myeloma Leu167Ile (c.499C>A) mutation prevents XBP1 mRNA splicing | Q86547190 | ||
| P433 | issue | 1 | |
| P921 | main subject | endoplasmic reticulum | Q79927 |
| multiple drug resistance | Q643839 | ||
| drug resistance | Q12147416 | ||
| P304 | page(s) | e1007 | |
| P577 | publication date | 2018-01-29 | |
| P1433 | published in | Clinical & translational immunology | Q27725955 |
| P1476 | title | Endoplasmic reticulum stress in the development of multiple myeloma and drug resistance | |
| P478 | volume | 7 |
| Q92496362 | Concurrent lipidomics and proteomics on malignant plasma cells from multiple myeloma patients: Probing the lipid metabolome |
| Q90671923 | DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway |
| Q90014292 | Endoplasmic reticulum and oxidative stress in immunopathology: understanding the crosstalk between cellular stress and inflammation |
| Q91713126 | Endoplasmic reticulum stress confers 5-fluorouracil resistance in breast cancer cell via the GRP78/OCT4/lncRNA MIAT/AKT pathway |
| Q97531602 | Immune system activation by natural products and complex fractions: a network pharmacology approach in cancer treatment |
| Q64107945 | Immunogenic Cell Death and Immunotherapy of Multiple Myeloma |
| Q89565340 | Molecular basis of clonal evolution in multiple myeloma |
| Q55091606 | Soluble and Cell-Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma. |
| Q64232735 | The PI3K/AKT signaling pathway regulates ABCG2 expression and confers resistance to chemotherapy in human multiple myeloma |
| Q95923721 | Tumour Cell Secretome in Chemoresistance and Tumour Recurrence |
Search more.